biotech firms expanding glp-1 use beyond diabetes and obesity 2025 Harvard Business Review | A PwC analysis shows that medications like Ozempic Zepbound may be catalyzing a behavioral and economic shift on par with major GLP-1 Weight Loss Drug Market

Multivitamins: A Comprehensive Nutrient Safety Net A high-quality multivitamin is often the cornerstone of a supplement routine

Migaya et al

Novel mineralocorticoid receptor antagonists (MRAs), such as finerenone, have shown potential in addressing the renal and cardiovascular components of CMS.85 These agents selectively block the mineralocorticoid receptor, reducing aldosterone-driven inflammation and fibrosis within the cardiovascular and renal systems.86 Unlike traditional MRAs, finerenone offers enhanced receptor selectivity and exhibited a lower risk of hyperkalemia, making it a safer option for CKD patients.86 Recent clinical trials, including the FIDELIO-DKD and FIGARO-DKD studies,85, 87 demonstrated that finerenone significantly slows CKD progression, reduces albuminuria, and lowers the incidence of cardiovascular events, such as heart failure hospitalizations and cardiovascular mortality

Ghrelin as an anti-sepsis peptide: review

(November 2009)